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The aim of this study was to estimate the direct medical costs of chronic obstructive pulmonary disease (COPD) in
the United States using a public-payor perspective. Cost estimates were derived separately for 10 components of
care using national survey databases and valued using Medicare and Medicaid reimbursement rates. COPD affects
15 million people in the U.S.A. and the total annual U.S. payment for care is $6?6 billion. Approximately one-third
($2?3 billion) is due to the cost of long-term oxygen therapy, one-quarter is attributed to hospitalizations and
inpatient physician services ($1?9 billion), and one-seventh ($942million) is due to nursing home stays. Other
annual costs are outpatient physician visits ($480million), prescription medications ($462million), home healthcare
($309million), emergency department visits ($148million), outpatient diagnostic procedures ($55million) and
hospice care ($28million). The cost of COPD is therefore considerable. The significant expenditure for long-term
oxygen therapy indicates that disease severity is a major driver of costs. However, the cost of hospitalizations,
nursing home stays, emergency department and physician visits are not insignificant.
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Chronic obstructive pulmonary disease (COPD) refers to
two related chronic respiratory disorders—emphysema and
chronic bronchitis (1). In 1986 it was estimated that 2
million people in the U.S.A. had emphysema and 11?4mil-
lion had chronic bronchitis (2). Projected to current
population estimates, this would suggest that 15million
people in the U.S.A. have COPD.
COPD rarely strikes before middle-age, because the
predominant risk factor is cigarette smoking or exposure to
environmental pollutants. There are an estimated 450 000
new cases per year (3). Prevalence increases with age, rising
in men from 7?5% at age 45–54 to 20% at age 75 and
over (4). COPD is a debilitating disease, ranking second
only to coronary disease as a cause of disability in persons
over 40 years of age (5). There is no known cure for COPD,
which is the fifth leading cause of death in the U.S.A. (6).
COPD is undoubtedly a costly disease. However,
published estimates that are available are limited and areReceived 5 October 1999 and accepted in revised form 25 July
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the cost of emphysema have been reported. Grossman (7)
estimated the total direct cost to be $171million annually in
1967 dollars. Freeman et al. (8) estimated it to be
$181?3million in 1970 dollars. Because the prevalence of
emphysema is only a fraction of COPD, it is likely that the
cost of COPD is five to 10 times higher than these estimates,
and considerably higher in current dollars. Unpublished
estimates of the direct cost of COPD including asthma were
placed at $7 billion in 1985 (2). Given the paucity of cost-
of-illness figures, the present analysis was undertaken to
estimate the annual cost of COPD.
Methods
A public-payor perspective was used to estimate the direct
cost of COPD. Intangible and indirect costs related to
COPD are not valued. Direct medical costs are dissected
into 10 components of care: hospitalization, inpatient
physician services, emergency department visits, outpatient
physician visits, outpatient diagnostic/screening proce-
dures, nursing home stays, hospice care, home healthcare,
prescription medications, and long-term oxygen therapy.
National survey databases, proprietary databases and
published literature comprise the sources of data used.
Medicare and Medicaid reimbursement rates are applied as
fee structures for valuing the services utilized (except# 2000 HARCOURT PUBLISHERS LTD
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ment’ refers to this fee structure and the term ‘annual cost’
is the product of this payment multiplied by the annual
utilization. Estimates apply to the U.S. alone and are
expressed in 1994 constant dollars.
For the present analyses, cases of COPD were identified
in the various datasets by extracting all encounters where
one of the following ICD-9 codes was listed in any of the
available diagnoses positions: 491, chronic bronchitis; 492,
emphysema; 496, unspecified obstructive pulmonary dis-
ease. The assessment of medical resource utilization was
restricted to those 45 years and older, because medical
resource utilization attributed to COPD is rare below this
age.
HOSPITALIZATIONS
Hospitalizations were valued by applying the national
average Medicare reimbursement (9) for each diagnosis-
related group (DRG) to the utilization data from the 1990
National Hospital Discharge Survey (10). This survey
contains information including the DRG assigned to the
hospitalization and the discharge diagnosis (up to seven
positions). We previously examined the effect of various
attribution rules and found (11) that hospitalization costs
should be estimated differently according to the DRG, as
described below.
COPD (DRG 88)
For medical management of COPD (DRG 88) 100% of the
cost of hospitalizations was attributed to COPD.
DRGs related to COPD
This portion captured hospitalizations for DRGs that are
prevalent in persons with COPD and frequently result from
the COPD. Costs of hospital admissions for patients with
COPD in any diagnosis position were adjusted for the age-
sex specific ‘background’ levels of hospitalizations for the
group of related DRGs1 in the non-COPD population.
Other DRGs
This portion captured hospitalizations for DRGs unrelated
to COPD. For these, incremental costs of hospitalizations
were computed based on the extent of additional length of1DRGs related to COPD were defined as the following: upper
respiratory infections (DRGs 68 –70), respiratory system OR
procedures (DRGs 76 –77), respiratory infections and inflamma-
tions (DRGs 79–81), pulmonary edema and respiratory failure
(DRG 87), pneumonia and pleurisy (DRGs 89 –91), interstitial
lung disease (DRGs 92–93), pneumothorax (DRGs 94 –95),
bronchitis and asthma (DRGs 96–97), respiratory signs and
symptoms (DRGs 99–100), other respiratory system diagnoses
(DRGs 101–102), respiratory system diagnosis with ventilator
support (DRG 475) and heart failure and shock (DRG 127).stay due to the COPD. This formula attributed 60% of the
daily cost of extended hospital days by COPD patients in
excess of the average length of stay for those without
COPD. The rationale for taking 60% rather than 100%
was that Medicare reimburses proportionately less for
lengths of stay beyond the national average corresponding
to each DRG because service and cost intensity generally
decline as a hospital stay progresses.
INPATIENT PHYSICIAN SERVICES
Information from the 1993 Medicare Public Use Files was
used to estimate the cost of inpatient physician services
associated with each DRG. These services were valued
using the reimbursement schedule specified in Part B of
Medicare’s billing system. Inpatient physician services were
then allocated using the same approach as described earlier
for hospital reimbursement.
EMERGENCY DEPARTMENT VISITS
Emergency department visits are reported in the Emergency
Department section of the 1993 National Hospital Ambu-
latory Medical Care Survey (12). In consideration of the
differential cost-intensities of emergency department visits,
we categorized emergency room visits based on the type of
specific screening, diagnostic and intervention services
rendered. Each category of emergency department visit
was matched to a specific CPT code (13) and corresponding
Medicare reimbursement rate (14). A portion of this cost
was allocated to COPD based on whether COPD was an
only-listed, first-listed, second-listed, or third-listed diag-
nosis and whether a related disorder2 was listed as a
diagnosis. If a related disorder was listed in addition to
COPD, more of the cost of the emergency department visit
was attributed to COPD because these conditions are likely
to be compounded by the COPD and/or a greater
percentage of the person’s care probably involved their
COPD.
OUTPATIENT PHYSICIAN VISITS
Outpatient physician visits are reported in two primary
surveys. The 1990 National Ambulatory Medical Care
Survey (NAMCS) samples outpatient physician visits that
occur for physicians in private practice or small group
practices (15). The National Hospital Ambulatory Medical
Care Survey (NHAMCS-OPV) was conducted in 1990 to
supplement the NAMCS by sampling outpatient visits by2Related disorders were defined as the following ICD-9 disease
codes: acute bronchitis and bronchiolitis (ICD-9 code 466),
pneumonia (ICD-9 codes 482 and 486), influenza (ICD-9 code
487), bronchitis (ICD-9 code 490), asthma (ICD-9 code 493), other
diseases of the lung (ICD-9 code 518), general symptoms (ICD-9
code 780), symptoms involving respiratory system and other chest
symptoms (ICD-9 code 786), disorders of fluid, electrolyte, and
acid-base balance (ICD-9 code 276) and heart failure (ICD-9 code
428).
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outpatient visit was matched to a specific CPT code (13)
and corresponding Medicare reimbursement rate (14). All
cases where COPD was listed as a diagnosis (in these
datasets there can be up to three diagnoses listed for each
visit), regardless of position, were weighted equally because
in most cases a diagnosis is listed in the NAMCS and
NHAMCS-OPV databases because it was brought to the
attention of the physician during the visit.
OUTPATIENT DIAGNOSTIC SCREENING
PROCEDURES
Chest X-rays are reported in both the 1990 NAMCS and
the 1990 NHAMCS-OPV. Spirometry and resting EKGs
are reported in only the NHAMCS-OPV. Thus levels of
resting EKG and spirometry use in NAMCS were
approximated by applying the corresponding rates of
utilization from NHAMCS-OPV. Once identified, CPT
codes (13) and Medicare reimbursement rates (14) were
assigned to these outpatient diagnostic and screening
procedures using the same procedure as that used for
outpatient physician visits.
NURSING HOME STAYS, HOME HEALTH
CARE, AND HOSPICE CARE
Utilization of nursing home services was determined using
data from the 1985 National Nursing Home Survey (17).
Utilization of home health care related to COPD was
estimated using the 1992 National Home and Hospice Care
Survey (18)—home healthcare component. Utilization of
hospice care related to COPD was estimated using the 1992
National Home and Hospice Care Survey (18)—hospice
care component. For each component of analyses, data
from the current residents sample were analysed to identify
persons with COPD who were receiving care on a given
day. The estimate of the number of person-days of service
was then converted to person-years of service provided.
These surveys list up to seven current diagnoses. The cost of
COPD was determined by component depending on
whether COPD was the only-listed diagnosis, first-listed,
or second-listed diagnosis. Decision rules for each compo-
nent were based on whether a related disorder3 was listed as
a diagnosis, and whether a serious disorder unrelated to
COPD4 was listed as a diagnosis. If a related disorder was
listed in addition to COPD, more of the cost of care was
attributed to COPD because these conditions were likely to
be compounded by the COPD and/or a greater percentage3Related disorders for nursing home care were defined as the
following ICD-9 codes: 276, 428, 466, 482, 486, 487, 490, 493, 518,
780, 786.
4Serious unrelated disorders for nursing care were defined as
disorders unrelated to COPD which are frequently the cause of
admission to nursing homes. These were: neoplasms (ICD-9 codes
140–240), dementia/mental disorders (ICD-9 codes 290–310),
degenerative CNS disease (ICD-9 code 333), hip fracture (ICD-9
code 820?8), and osteoporosis (ICD-9 code 733).of the person’s care probably involved their COPD. If a
serious unrelated disorder was listed, less of the cost of care
was attributed to COPD because a person with one of these
serious unrelated disorders was likely to be receiving care
whether or not they had COPD. The yearly charge for
Medicaid was used to value annual medical resource
utilization of nursing home services. Medicare reimburse-
ment rates were used to value home healthcare and hospice
care.
PRESCRIPTION MEDICATIONS
NAMCS was used to estimate the proportion of prescrip-
tions for various bronchodilators that were provided to
patients with COPD. These proportions were applied to the
total expenditures for the same classes of bronchodilators
as reported in the 1987 National Medical Expenditure
Survey (NMES). Expenditures on prescription medications
reported in NMES were adjusted from 1987 to 1994 dollars
using a medication-specific Consumer Price Index multi-
plier and for a 20% under-reporting generally found with
NMES (19). Proprietary data obtained from IMS and
Scott-Levin were used to estimate the cost (at AWP rates)
for anti-inflammatory drugs used by COPD patients.
LONG-TERM OXYGEN THERAPY
The use of home oxygen therapy was not included in any of
the available national medical resource utilization surveys.
However, there are recent estimates in the literature.
O’Donahue and Plummer (20) estimated, based on U.S.
General Accounting Oce reports, that there were 616 000
patients using home oxygen therapy in 1993. By contacting
oxygen therapy vendors, we determined that the cost of
oxygen therapy is almost entirely in the fixed cost of the
equipment and is not dependent on the amount of oxygen
consumed. Medicare reimbursement policy is consistent
with this and is a fixed rate, dependent on whether oxygen is
supplied in forms suitable for ambulatory use or not. For
stationary administration, in 1994 Medicare reimbursed at
$309 per month. For short-term ambulatory administra-
tion, such as that needed to leave the house for an
outpatient physician visit, Medicare reimbursed at $49 per
month.
Results
As shown in the third column in Table 1, about one third of
the cost of hospitalizations for persons with COPD were for
DRG 88—medical management of COPD. More than half
of the cost was for hospitalizations where persons with
COPD had other respiratory conditions. The incremental
analysis of the effect of COPD on length of stay for
hospitalizations unrelated to COPD indicates a slightly
longer stay for persons with COPD compared to persons
without. The annual U.S. payment for hospitalizations for
COPD is $1?6 billion. On a per-hospitalization basis, the
average cost for these services is $2361. The cost of
TABLE 1. Allocated cost of hospitalizations and inpatient physician services attributed to COPD by DRG
Type of DRG Projected
number of
hospitalizations
Annual U.S.
incremental payment
for hospitalizations
Annual U.S.
incremental payment
for inpatient MDs
DRG 88 (COPD) 201 109 $627 614 933 $103 382 949
Related DRGs 456 604 $979 420 289 $151 876 960
Other DRGs 23 834 $2 605 498 $938 237
Total 681 547 $1 609 640 720 $256 198 146
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of Table 1. Total annual U.S. payment for inpatient
physician services for COPD is $256million. The average
per-hospitalization cost for these services is $376.
The annual U.S. payment for emergency department
visits for COPD is $148million. On a per-visit basis, the
average cost for these services is $237. COPD was the only-
coded diagnosis for 42% of the visits, was the first-listed
diagnosis for 38% of the visits, was the second-listed
diagnosis for 15% of the visits, and was the third-listed
diagnosis for only 5% of the visits. Thus, in contrast to
hospitalizations, emergency department visits were coded
with fewer diagnoses and co-morbidities were frequently
not noted.
The annual U.S. payment for COPD-related outpatient
physician visits from NAMCS is $156 million and the
average per-visit cost for a COPD-related outpatient
physician visit is $25. The annual U.S. payment for
COPD-related outpatient physician visits from
NHAMCS-OPV is $7?8million and the average per-visit
cost for a COPD-related outpatient physician visit is $27.
The total indicates that the annual U.S. payment for
COPD-related outpatient physician visits from NAMCS
and NHAMCS-OPV combined is $164million. In our
previous experience we have found that the combined
NAMCS and NHAMCS-OPV datasets underestimate this
component of care. In the present case, the utilization rates
projected from these databases would indicate that persons
with COPD average only one outpatient physician visit per
year. Pulmonologists who consulted to this project were
asked for estimates of the frequency of outpatient physician
visits in persons with COPD. They estimated that of
patients who were under care, those with mild COPD
average two visits per year, those with moderate COPD
average three visits per year and those with severe COPD
average 6?7 visits per year. Using these figures and estimates
on the number of patients with COPD who are under
treatment, we estimated the average annual number of
visits. Comparison with the totals derived using NAMCS
and NHAMCS-OPV revealed that the expert consultant’s
estimates were 2?94 times higher than the estimates based
on these surveys. Consequently, an adjustment of 2?94
times was applied to the utilization rates estimated from
NAMCS and NHAMCS-OPV. The projected total U.S.
payment, $480million, is adjusted by multiplying the costderived from NAMCS and NHAMCS-OPV by this factor.
Fifty-eight percent of the outpatient physician visits coded
for COPD have it as the first-listed diagnosis.
The annual U.S. payment for diagnostic/screening
procedures for COPD is $55million. Eighty-four percent
of the cost of diagnostic/screening services was for chest X-
rays and 15% was for resting EKG with only 1% for
spirometry. Dividing the total by the number of outpatient
visits (including visits with no diagnostic or screening
procedures), we find that the average per-visit cost for
COPD-related diagnostic/screening procedures is $8?43.
The cost estimates for COPD-attributed nursing home
care are presented in the second and third columns of
Table 2. Twelve percent of the total cost was for COPD as
the only-listed diagnosis, 61% as the first-listed diagnosis,
and 27% as the second-listed diagnosis. The total indicates
that the annual U.S. payment for nursing home care for
COPD is $942million and the average yearly attributable
cost for 1 year of COPD-related nursing home care is
$17 868.
The fourth and fifth columns of Table 2 present the costs
for hospice care and show that 37% of the total cost was for
COPD as the only-listed diagnosis, 36% as the first-listed
diagnosis, and 27% as the second-listed diagnosis. The total
indicates that the annual U.S. payment for hospice care for
COPD is $28million and the average attributable cost for
one-year of COPD-related hospice care is $17 274.
As shown in the right two columns of Table 2, 14% of
the total cost of home healthcare was for COPD as the
only-listed diagnosis, 46% as the first-listed diagnosis and
40% as the second-listed diagnosis. The total indicates that
the annual U.S. payment for home healthcare for COPD is
$309million and the average attributable yearly cost for
COPD-related care is $5386.
The total cost of bronchodilators and anti-inflammatory
drugs in the NMES was $840 965 732. Applying the
percentage utilization due to COPD from the NAMCS
yielded an annual expenditure for bronchodilators and
anti-inflammatory drugs attributed to COPD of
$307 445 644. Adjusting for an estimated 20% under-
reporting and adding an estimated 14?9% market share
for corticosteroid inhalants ($68 824 220) and an estimated
1?9% market share for non-sterodial (inhaled) anti-
inflammatory drugs ($8 776 243) brought the total to
$462million annually.
TABLE 2. Allocated cost of nursing home stays, hospice care and home healthcare attributed to COPD by position of diagnosis
Nursing home stays Hospice care Home healthcare
Position of COPD
as diagnosis
Projected
number of
person-years
Annual U.S.
payment
Projected
number of
person-years
Annual U.S.
payment
Projected
number of
person-years
Annual U.S.
payment
Only-listed 4401 $117 977 740 511 $10 252 465 7407 $43 548 479
First-listed 29 377 $571 201 482 336 $10 104 419 25 349 $141 547 692
Second-listed 18 947 $252 907 312 773 $7 626 588 24 692 $124 321 886
Total 52 725 $942 086 534 1620 $27 983 469 57 448 $309 418 057
TABLE 3. Total annual direct medical costs of COPD by
component of care
Type of cost Annual U.S.
cost
Percent
Hospitalizations $ 1 609 640 720 24%
Inpatient physician services $ 256 198 146 4%
Emergency department visits $ 147 909 508 2%
Outpatient physician visits $ 480 471 525 7%
Outpatient diagnostic
procedures
$ 54 963 720 1%
Nursing home stays $ 942 086 534 14%
Hospice care $ 27 983 469 51%
Home health care $ 309 418 057 5%
Prescription medication $ 461 907 519 7%
Long-term oxygen therapy $ 2 284 128 000 35%
Grand total $ 6 574 707 198 100%
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hue and Plummer’s (20) calculation that 616 000 persons
receive home oxygen therapy annually in the United States.
Multiplying this number of persons receiving oxygen by our
estimate of the yearly cost ($3708) yields an annual U.S.
payment for long-term oxygen therapy for COPD of
$2?3 billion.
Discussion
The cost-of-illness analysis presented here estimates the
total annual U.S. payment for care for COPD to be
$6?6 billion. There are very few reports available with which
to compare this finding. The estimates that are available are
either for a portion of COPD or for COPD lumped with
another disorder. For example, two estimates of the cost of
emphysema have been reported. Grossman (7) estimated
the total direct cost to be $171million annually in 1967
dollars. Freeman et al. (8) estimated it to be $181?3million
in 1970 dollars. These estimates, projected to current
dollars, expressed on a per patient basis, and extrapolated
to the prevalence for COPD, would be $8?7 billion and
$7?4 billion, respectively. Unpublished estimates of the
direct cost of COPD plus asthma in 1985 were placed at
$7 billion (2), which would convert to $13 billion when
inflated. Clearly, the current finding is in the ballpark of
these previous estimates for related conditions. The paucity
of suitable comparisons points to the need for more
research in this area.
In addition to deriving the total annual cost of COPD,
the present analysis estimated the cost for each of 10 major
components of care. As shown in Table 3, of the $6?6 billion
total, one-third ($2?3 billion) is attributed to the cost of
long-term oxygen therapy, about one-quarter is attributed
to hospitalizations and inpatient physician services
($1?9 billion), and about one-seventh ($942million) is due
to nursing home stays. Other costs incurred annually by the
U.S. population with COPD are outpatient physician visits
($480million), prescription medications ($462million),
home healthcare ($309million), emergency department
visits ($148million), outpatient diagnostic procedures
($55million), and hospice care ($28million).
These estimates of the portion of total cost for each
component of care reflect the healthcare utilization typicalof persons with symptomatic COPD. The dollar amount
differs, but the relative proportions of cost attributed to
hospitalizations, outpatient visits and medications in the
current analysis are the same as those reported by Freeman
(8) for emphysema.
With serious diseases, often hospitalizations are by far
the largest cost factor. However, with COPD, surgical
hospitalizations have been rare (this may be less true today
with the number of lung reduction surgeries that are being
conducted), decreasing by some degree the frequency and
cost of hospitalizations that might be expected in a
population with a serious disease. Still, hospitalizations
are the second largest cost factor, reflecting the fact that
persons with COPD are hospitalized for the medical
management of that disease and for treatment of other
illnesses (e.g. pneumonia) for which COPD is a prime risk
factor. In addition, the analysis indicates that persons with
COPD who are hospitalized for co-morbidities unrelated to
their COPD, do have a slightly longer length of stay, thus
incurring additional costs. Thus, persons with COPD have
substantial hospitalization costs due to COPD.
The third largest cost factor is for nursing home
care, reflecting the fact that COPD is debilitating and
strikes older populations. The need for this type of
1128 M. M. WARD ET AL.assistance and daily care is also reflected in the cost of home
healthcare.
In contrast to other serious and/or chronic conditions,
the proportion of healthcare costs spent on prescription
medications by persons with COPD is relatively low. This
probably reflects several factors. First, there are no
pharmacotherapies currently available that are effective in
controlling the disease process. Second, currently available
pharmacotherapies provide only partial symptomatic relief,
a factor that often leads to diminished compliance and low
refill rates. Third, many of these drugs are available in
generic forms, which decreases cost. Fourth, the classes of
drugs that are used for COPD are less expensive than drugs
available for some other serious diseases (e.g. cancer,
AIDS).
The finding that oxygen therapy represents one-third of
the total cost is probably surprising at first glance.
However, hypoxemia is the primary consequence of
moderate and severe COPD. Persons with moderate COPD
have nocturnal hypoxemia and rely on stationary oxygen,
persons with severe COPD have day and night hypoxemia,
and rely on both stationary and ambulatory oxygen. Near-
continuous home oxygen therapy has been shown to
prolong life in persons with severe COPD (21) and is the
only therapy, to date, that has been shown to do so. Oxygen
therapy is expensive, costing $3700 per patient, on average,
per year (22). An estimated 80% of this cost is borne by
HCFA (20), thus our use of Medicare costing for this
component of care is particularly appropriate. Because of
the cost of home oxygen therapy, HCFA has recently
scrutinized the appropriateness of care, and set guidelines
for the prescription of oxygen using the criteria from the
original NOTT trial (23).
The cost-effectiveness of various attempts to improve
care for persons with COPD has been investigated (24).
Some approaches have focussed on finding more cost-
effective drug therapies (25–28). Other approaches have
used enhanced educational programs (29), outpatient
rehabilitation programs (30), and home-based care pro-
grams (3,31). Reports of the cost-effectiveness of these
various approaches have been mixed.
New pharmaceuticals are in development for COPD with
the hope that they can not only provide improved symptom
relief, but also slow or reverse the disease process. Much of
the cost of treating COPD occurs in the later stages of the
disease and is almost entirely driven by the need for oxygen
to reduce the associated hypoxemia. In order to produce
significant reductions in the cost of the disease, the need for
oxygen therapy must be reduced.
Treatment aimed at improving quality of life and
potentially enhancing survival, rather than on producing
significant reductions in the cost of disease, is likely most
appropriate for patients suffering from end-stage COPD.
Current therapy should focus on smoking cessation as well
as improving symptoms in patients with moderate to severe
COPD. Early detection and intervention in smokers with
evidence of lung function decline should not be under-
estimated in reducing future morbidity and associated costs
by delaying progression to disability. However, new
therapies to improve quality of life and to reducemorbidity, disease progression, and healthcare utilization
in the form of physician visits and hospitalizations are
urgently needed and will have considerable impact in
reducing the cost of treating all stages of COPD.
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